Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemicentin-2 (HMCN2)
- Target
- HMCN2
- Molecular classification
- Extracellular matrix protein, Fibulin family, Immunoglobulin superfamily domain-containing protein
01
Overview
Hemicentin-2 is a large, evolutionarily conserved extracellular matrix glycoprotein that plays a crucial structural role in the organization and stabilization of diverse tissues and organs. It is structurally related to, but distinct from, the classic fibulin family, characterized by multiple immunoglobulin-like domains and a von Willebrand A (vWA) domain. Hemicentin-2 is secreted by epithelial cells, prominently at junctional interfaces such as the dermal–epidermal and myotendinous junctions, where it contributes to basement membrane linkage and proper tissue adhesion. In animal models, it is essential for successful cytokinesis, tissue fusion, and normal morphogenesis. Human genetic studies link HMCN2 variation to susceptibility to connective tissue disorders, certain forms of cardiac valve disease, and neurodegeneration, likely via its fundamental role in extracellular matrix composition and cell adhesion. No drugs currently target Hemicentin-2, and its biological mechanisms, while essential for developmental tissue stability, are incompletely understood.
- Other names
- Hemicentin 2HMCN2DKFZp434P0216FLJ23816Fibulin-8 (outdated/partial usage)HEMICENTIN-2
02
Mechanism of action
Not applicable
03
Biological functions
Extracellular matrix assembly and stabilization: Structural support for tissue junctions and basement membranesHomophilic cell adhesion: Via plasma membrane adhesion moleculesSynapse organizationTissue morphogenesis: Roles in epithelial and mesenchymal cell migration and fin/tissue developmentRegulation of cytokinesis: Contributes to cleavage furrow maturation and successful cell division during embryogenesisAxon guidance receptor activity (predicted, not definitively demonstrated in humans)
04
Disease associations
Connective tissue disorders (e.g., involvement in inguinal hernia susceptibility)Cardiovascular disease (bicuspid aortic valve degeneration via possible effects on calcium metabolism)Neurodegenerative disease (genetic associations with Alzheimer’s disease risk and lipid metabolism)Other developmental defects (e.g., defective epidermal–dermal junction formation in model organisms)
05
Safety considerations
Not applicable in the context of therapeutic targeting; however, loss-of-function mutations may affect embryonic tissue development and integrity, but no specific therapeutic safety risks are described
06
Interacting drugs
None known
07
Biomarkers
No established clinical biomarkers; differential expression or genetic variation may provide future research markers in connective tissue or neurodegeneration, but none are established for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Hemicentin-2 (HMCN2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemicentin-2 (HMCN2).